Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

[1]  P. Wiedemann,et al.  Treatment patterns, visual acuity and quality‐of‐life outcomes of the WAVE study – A noninterventional study of ranibizumab treatment for neovascular age‐related macular degeneration in Germany , 2013, Acta ophthalmologica.

[2]  D. Boyer.  A Phase 2b Study of Fovista™, a Platelet Derived Growth Factor (PDGF) inhibitor in combination with a Vascular Endothelial Growth Factor (VEGF) inhibitor for Neovascular Age-Related Macular Degeneration (AMD) , 2013 .

[3]  D. Preen,et al.  MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS: A Whole Population Study , 2013, Retina.

[4]  A. Barak,et al.  Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). , 2013, Ophthalmology.

[5]  L. Schmetterer,et al.  A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration , 2013, British Journal of Ophthalmology.

[6]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[7]  C. Bell,et al.  Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study , 2012, BMJ : British Medical Journal.

[8]  G. Ying,et al.  Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡* , 2012 .

[9]  Usha Chakravarthy,et al.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.

[10]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[11]  T. Wong,et al.  Changing trends of blindness: the initial harvest from translational public health and clinical research in ophthalmology. , 2012, American journal of ophthalmology.

[12]  A. Foss,et al.  Risks of adverse events with therapies for age-related macular degeneration: a response. , 2012, Archives of ophthalmology.

[13]  P. Mitchell,et al.  Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? , 2011, American journal of ophthalmology.

[14]  A. Messori,et al.  Treatments for macular degeneration: summarising evidence using network meta-analysis , 2011, British Journal of Ophthalmology.

[15]  P. Mitchell.  A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab , 2011, Current medical research and opinion.

[16]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[17]  S. Sengupta,et al.  Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration , 2011, Indian journal of ophthalmology.

[18]  A. Joussen,et al.  The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279 , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[19]  P. Mitchell,et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis , 2010, BMC ophthalmology.

[20]  K. Schulman,et al.  Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. , 2010, Archives of ophthalmology.

[21]  L. da Cruz,et al.  Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study , 2010, BMJ : British Medical Journal.

[22]  C. Bradley,et al.  Measuring Quality of Life in Macular Degeneration , 2010 .

[23]  Victor R. Preedy,et al.  Handbook of disease burdens and quality of life measures , 2010 .

[24]  A. Houranieh,et al.  Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. , 2009, American journal of ophthalmology.

[25]  G. Quentel,et al.  Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. , 2009, American journal of ophthalmology.

[26]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[27]  M. Maia,et al.  PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up , 2008, Retina.

[28]  Douglas G. Altman,et al.  Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .

[29]  Martin Rubinstein,et al.  The MacDQoL individualized measure of the impact of macular degeneration on quality of life: reliability and responsiveness. , 2008, American journal of ophthalmology.

[30]  R. Karas,et al.  The safety of niacin in the US Food and Drug Administration adverse event reporting database. , 2008, The American journal of cardiology.

[31]  Paul Mitchell,et al.  Clinical update: new treatments for age-related macular degeneration , 2007, The Lancet.

[32]  Christine M. Cheng,et al.  Bevacizumab for Neovascular Ocular Diseases , 2007, The Annals of pharmacotherapy.

[33]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[34]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[35]  Sander R. Dubovy,et al.  SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[36]  R. Spaide,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE , 2006, Retina.

[37]  Helen Brown,et al.  Applied Mixed Models in Medicine , 2000, Technometrics.

[38]  U Chakravarthy,et al.  Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? , 2000, The British journal of ophthalmology.

[39]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[40]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[41]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[42]  Denis G. Pelli,et al.  THE DESIGN OF A NEW LETTER CHART FOR MEASURING CONTRAST SENSITIVITY , 1988 .

[43]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[44]  I L Bailey,et al.  New Design Principles for Visual Acuity Letter Charts* , 1976, American journal of optometry and physiological optics.